Background Osteogenesis imperfecta (OI) is a rare disease with an estimated incidence of between 1/25,000 and 1/10,000 globally. The main treatment for OI is the administration of bisphosphonate drugs. Research on clinical, radiographic, and biochemical markers to monitor patients with OI treated with zoledronate can be challenging in countries in which patients have limited national health insurance. We aimed to examine patients with OI treated in Indonesia with a minimum follow-up period of 2 years.
Methods An observational study was conducted of all patients with OI treated with zoledronate between 2021 and 2023 at a tertiary hospital in Indonesia. We evaluated the paediatric quality of life (PedsQL), bone mineral density (BMD), and alkaline phosphatase (ALP) level before and after zoledronate treatment. To monitor safety, serum creatinine and calcium levels were also measured.
Results Eleven boys (55%) and nine girls (45%), with an average age of 6.9 years (range, 4–17 years), were included. After 2 years of zoledronate treatment, the total PedsQL score increased from 66.7 to 76.9 (P=0.0001) and the mean lumbar and total body BMD increased from 0.467 and 0.501 to 0.599 g/cm2, and 0.626 g/cm2 (P=0.001), respectively. The ALP level decreased from 310.6 to 186.4 mg/mL (P=0.0001). Neither serum creatinine (P=0.586) nor calcium (P=0.53) levels changed from the pre-treatment to 2 years post-treatment time points.
Conclusions Zoledronate was safe and effective for the treatment of OI. There were significant improvements in the quality of life and BMD in patients with OI. The ALP level decreased, but serum creatinine and calcium levels were not affected by zoledronate.
Citations
Citations to this article as recorded by
1. Fracture risk assessment by dual-energy absorptiometry in osteogenesis imperfecta: A systematic review of measurement sites and its predictive value Karlijn Scheepens, Suzanne den Haan, Kelly Warmink, Ralph Sakkers, Anne Spaans, Wouter Nijhuis, Harrie Weinans Bone Reports.2026; 30: 101929. CrossRef
2. Health-Related Quality of Life and Fatigue in Patients with Osteogenesis Imperfecta Filiz Mercan Sarıdaş, Erhan Hocaoğlu, Müge Yaşar, Kadircan Karatoprak, Güven Özkaya, Soner Cander, Erdinç Ertürk, Canan Ersoy, Özen Öz Gül Healthcare.2026; 14(12): 1620. CrossRef
Background A rapid increase in bone turnover and bone loss has been observed in response to the discontinuation of denosumab. It led to an acute increase in the fracture risk, similar to that observed in the untreated patients. We aimed to investigate the effect of denosumab on osteoclast (OC) precursor cells compared to that of zoledronate.
Methods The study compared the effects of denosumab (60 mg/24-week) and zoledronate (5 mg/48-week) over 48 weeks in postmenopausal women with osteoporosis. From patients’ peripheral mononuclear cells, CD14+/CD11b+/vitronectin receptor (VNR)- and CD14+/CD11b+/VNR+ cells were isolated using fluorescent-activated cell sorting, representing early and late OC precursors, respectively. The primary endpoint was the changes in OC precursors after 48 weeks of treatment.
Results Among the 23 patients, 11 were assigned to the denosumab group and 12 to the zoledronate group (mean age, 69 years). After 48 weeks, the changes in OC precursors were similar between and within the groups. Serum C-terminal telopeptide of type I collagen levels were inversely correlated with OC precursor levels after denosumab treatment (r=-0.72, P<0.001). Lumbar spine, femur neck, and total hip bone mineral density (BMD) increased in both groups. Lumbar spine BMD increased more significantly in the denosumab group than in the zoledronate group.
Conclusions Denosumab and zoledronate treatments induced similar changes in OC precursors. During denosumab treatment, old age and suppressed bone turnover were associated with increased OC precursor cell populations. Further validation studies with prospective designs are required.
Citations
Citations to this article as recorded by
1. Efficacy and Safety of Denosumab and Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis—A Comparative Study of Bone Metabolism, Bone Density, and Sex Hormone Levels Huiling Tang, Jinyan Chen, Xufeng Fan Journal of Applied Toxicology.2026; 46(5): 1530. CrossRef
2. Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone loss Federico Aldegheri, Angelo Fassio, Matteo Appoloni, Denise Rotta, Francesca Ruzzon, Davide Bertelle, Giovanni Adami, Davide Gatti, Maurizio Rossini, Ombretta Viapiana Osteoporosis International.2026; 37(4): 983. CrossRef
3. Progress on novel compounds for the treatment of bone metabolism-related disorders: focus on osteoporosis and beyond Yeqiong Song, Ruixing Zhang, Xinyue Zhang, Jingkai Wang, Jinyang Chen, Li Li Frontiers in Chemistry.2026;[Epub] CrossRef
4. The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation Marian Schini, Fatma Gossiel, Tanya Saini, Peter Banda, Rachel Ward, Tatiane Vilaca, Richard Eastell, Andreas Fontalis Journal of Bone and Mineral Research.2025; 40(3): 301. CrossRef
5. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures Shejil Kumar, Mawson Wang, Albert S Kim, Jacqueline R Center, Michelle M McDonald, Christian M Girgis Journal of Bone and Mineral Research.2025; 40(9): 1017. CrossRef
6. Denosumab Withdrawal and Rebound Bone Resorption: Molecular Mechanisms and Approaches for Treatment Anish Rajamohanan Jalaja, Aswathy Nair Current Stem Cell Reports.2025;[Epub] CrossRef
7. Positive und negative (Neben)Effekte bei
Osteoporose-Sequenztherapie Barbara Obermayer-Pietsch, Ines Fößl, Friederike Thomasius Osteologie.2024; 33(02): 80. CrossRef
8. Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review) N. Yu. Velts, O. V. Velts, R. N. Alyautdin Safety and Risk of Pharmacotherapy.2024; 12(2): 190. CrossRef
9. Cellular signatures in human blood track bone mineral density in postmenopausal women Kaichi Kaneko, Jefferson Tsai, Deniece Meñez, Brian Oh, Andrew Junwoo Suh, Seyeon Bae, Masataka Mizuno, Akio Umemoto, Eugenia Giannopoulou, Takayuki Fujii, Yaxia Zhang, Emily M. Stein, Richard S. Bockman, Kyung-Hyun Park-Min JCI Insight.2024;[Epub] CrossRef
10. Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment Chiao-Ling Chen, Jian-Ying Wang Frontiers in Endocrinology.2024;[Epub] CrossRef
11. Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han Orthopaedic Surgery.2023; 15(1): 256. CrossRef
12. Long-term and sequential treatment for osteoporosis Ines Foessl, Hans P. Dimai, Barbara Obermayer-Pietsch Nature Reviews Endocrinology.2023; 19(9): 520. CrossRef
Background Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab.
Methods Twelve patients who received at least 2 doses of denosumab followed by at least 1 dose of ZA and who had a dual energy X-ray absorptiometry (DXA) scan at the end of denosumab and 1 year after the first dose of ZA were included. We excluded patients with bone cancer or conditions affecting bone metabolism, including hyperparathyroidism, rickets, osteogenesis imperfecta, rheumatologic disorders, fibrous dysplasia, Paget’s disease of bone, untreated hyperthyroidism, chronic kidney disease, liver cirrhosis, malabsorption, ongoing corticosteroid therapy, and aromatase inhibitor use.
Results There was a significant decline in BMD at the femoral neck within 1 year of the first ZA dose and a non-significant downward trend in the hip and lumbar spine. This trend was more severe in patients with osteoporosis at the time of drug transition. No increase in clinical vertebral fractures was observed. BMD seemed to stabilize in a smaller number of patients who received a second dose of ZA and had a DXA scan 1 year later.
Conclusions A single dose of ZA administered approximately 6 months after denosumab leads to some BMD loss, mostly within 1 year of ZA administration, particularly in patients with osteoporosis at the time of denosumab discontinuation.
Citations
Citations to this article as recorded by
1. Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How? Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang Clinical Pharmacology & Therapeutics.2026; 120(2): 334. CrossRef
2. Osteoporosis as a chronic disease: an expert narrative review and practical recommendations on long-term management and sequential therapy after denosumab discontinuation Sandro Giannini, Davide Gatti, Andrea Giusti, Gregorio Guabello, Stefano Lello, Andrea Palermo, Luigi Gennari Endocrine.2026;[Epub] CrossRef
3. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures Shejil Kumar, Mawson Wang, Albert S Kim, Jacqueline R Center, Michelle M McDonald, Christian M Girgis Journal of Bone and Mineral Research.2025; 40(9): 1017. CrossRef
4. Effectiveness of Sequential Treatment with Zoledronic Acid Following Discontinuation of Denosumab in Osteoporosis: A Narrative Review Hong Ouyang, Fan Yang, Wenzuo Wei, Wei Wang Drug Design, Development and Therapy.2025; Volume 19: 10013. CrossRef
5. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis Ta-Wei Tai, Hsuan-Yu Chen, Chien-An Shih, Chun-Feng Huang, Eugene McCloskey, Joon-Kiong Lee, Swan Sim Yeap, Ching-Lung Cheung, Natthinee Charatcharoenwitthaya, Unnop Jaisamrarn, Vilai Kuptniratsaikul, Rong-Sen Yang, Sung-Yen Lin, Akira Taguchi, Satoshi Mo Osteoporosis and Sarcopenia.2024; 10(1): 3. CrossRef
6. Zoledronic acid relieves steroid-induced avascular necrosis of femoral head via inhibiting FOXD3 mediated ANXA2 transcriptional activation Yu Lin, Min Chen, Wenbin Guo, Shengliang Qiu, Lihui Chen, Wenge Liu Bone.2024; 188: 117222. CrossRef
7. A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis Zhanna Belaya, Liudmila Rozhinskaya, Ivan Dedov, Oksana Drapkina, Valentin Fadeev, Olga Golounina, Olga Lesnyak, Elizaveta Mamedova, Galina Melnichenko, Alexey Petraikin, Svetlana Rodionova, Irina Skripnikova, Olga Tkacheva, Natalia Toroptsova, Svetlana Y Osteoporosis International.2023; 34(3): 429. CrossRef
8. Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? Christian Horst Tonk, Sarah Hani Shoushrah, Patrick Babczyk, Basma El Khaldi-Hansen, Margit Schulze, Monika Herten, Edda Tobiasch International Journal of Molecular Sciences.2022; 23(3): 1393. CrossRef
9. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis Namki Hong, Sungjae Shin, Seunghyun Lee, Kyoung Jin Kim, Yumie Rhee Calcified Tissue International.2022; 111(1): 47. CrossRef
10. Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab Jung-Wee Park Journal of Bone Metabolism.2021; 28(4): 339. CrossRef